HLB Co., Ltd. (KOSDAQ:A028300) agreed to acquire an additional 46.4% stake in Immunomic Therapeutics, Inc. for KRW 35.6 billion on February 19, 2020. As per the transaction, HLB Co., Ltd. will acquire additional 6 million shares and the consideration will be paid in cash. Post completion, HLB Co., Ltd. will hold 8 million shares representing 61.9% stake of Immunomic Therapeutics, Inc. The Board of Directors of HLB Co., Ltd. passed the resolution for the transaction. Completion is scheduled on April 30, 2020. BDO Limited - Thailand acted as due diligence provider to HLB Co., Ltd.